When does nivolumab patent expire?

There isn’t a single expiration date for nivolumab. It’s protected by a portfolio of patents (composition of matter, methods of use, manufacturing, etc.), and expiry depends on the country and the specific patent family. In general:

- The main composition-of-matter patents for nivolumab are expected to expire in the late 2020s in major markets (with potential term adjustments that can push some dates further into the late 2020s or early 2030s in certain jurisdictions).
- In the United States, even after patent expiry, there is 12 years of data exclusivity for new biologics, which can delay biosimilar competition (roughly through 2026–2027 for nivolumab’s approval in 2014).
- In the European Union and other markets, data exclusivity and market exclusivity may also delay biosimilar entry for a number of years.

If you want a precise date, tell me the country/jurisdiction and whether you’re asking about the composition-of-matter patent or a use/manufacturing patent, and I can pull the current expiry dates for those specific patent families.